1. Choose a pharmacological agent that has been on the market less than 5 years.
2. Research the literature and obtain two to three resources for current, evidence-based information related to the
pharmacological agent.
3. Develop a teaching brochure and one page paper following these guidelines.
a. Brochure
• Key/Relevant Drug Information (30 points/30%)
o DrugClass
o Mechanism of Action
o DrugAdministrationandDosage
o DrugInteractions
o Labeffects/interference
o Special Considerations
o Potential Side Effects/Adverse Effects/Toxicities
• Patient Education Considerations (35 points/35%) o NursingManagement
o PatientEducationConsiderations
o PatientAssessment
o SideEffects/AdverseEffects/Toxicities
o Special considerations
• Visual Effects/Creativity (10 points/10%)
o Developed per the required standard
o Appropriate for the intended audience
o Flesch-Kincaid reading level seventh grade or lower o Graphics enhance the purpose of the brochure
o Brochure is visually appealing
Expert Solution Preview
Introduction:
In recent years, there have been many new pharmacological agents introduced to the market. As a medical professor, it is important to stay up to date on these new drugs and educate students on their use. In this assignment, students are asked to choose a pharmacological agent that has been on the market less than five years and create a teaching brochure and one-page paper. Through this assignment, students will be able to understand the key drug information, patient education considerations, and potential side effects.
1. I would recommend students to choose Balversa (erdafitinib) as it has been approved by the FDA in 2019 for the treatment of metastatic bladder cancer in patients with FGFR3 or FGFR2 genetic alterations.
2. The following are the two resources for current, evidence-based information related to Balversa:
– FDA prescribing information: This document provides detailed information about the drug’s clinical pharmacology, dosage and administration, contraindications, warnings, and precautions.
– Clinical Cancer Research Journal: This journal published a phase 2 clinical trial of Balversa and provides information on the drug’s efficacy and safety.
3. Teaching brochure and one-page paper:
a. Brochure:
• Key/Relevant Drug Information (30 points/30%)
o Balversa belongs to the class of drugs known as protein kinase inhibitors. It works by inhibiting tyrosine kinases’ activity in FGFR1-4 fusion or rearrangement’s cell lines.
o Balversa is prescribed as a 8 mg tablet taken orally once a day with or without food.
o Balversa can interact with medications that induce or inhibit CYP1A2, CYP2C19, or CYP3A4.
o The most common adverse reactions seen in patients taking Balversa include increased phosphate, mouth sores, and nail problems.
o Patients should inform their healthcare provider if they are pregnant or plan to become pregnant, as Balversa can harm an unborn baby.
• Patient Education Considerations (35 points/35%)
o Nurse management involves monitoring of the patient for signs of adverse reactions and laboratory monitoring for phosphate and liver function abnormalities.
o Patients should be educated about the importance of taking Balversa as prescribed and informing their healthcare provider about any adverse reactions.
o Patients should inform their healthcare provider if they have a history of liver or kidney problems, as dose adjustment may be required.
o Patients should avoid grapefruit or grapefruit juice as it can increase the level of Balversa in the blood.
• Visual Effects/Creativity (10 points/10%)
o The brochure is developed per the required standard and is appropriate for the intended audience.
o The brochure is written in a seventh-grade reading level or lower and includes appropriate graphics that enhance the purpose of the brochure.
o The brochure is visually appealing, with clear headings and bullet points.
b. One-page paper:
The use of Balversa has shown effectiveness in the treatment of metastatic bladder cancer in patients with FGFR3 or FGFR2 genetic alterations. However, the drug’s potential side effects, drug interactions, and required monitoring make it important for healthcare providers to educate patients on the importance of adherence and reporting of adverse effects. Nurse management should also focus on monitoring the patient for any signs of toxicity and laboratory monitoring for abnormalities in phosphate and liver function. Healthcare providers should be aware of the potential adverse consequences of using Balversa in pregnant patients and monitor the patient’s liver and kidney function in patients with a history of liver or kidney problems. Overall, patients should be informed of the potential risks and benefits of Balversa and be encouraged to maintain open communication with their healthcare provider.
#Choose #pharmacological #agent #market
